MedTrace Logo

Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)

NCT01934504 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2016-05-20

Study results available
· View outcomes & findings →

Summary

The goal of the study is to find biological markers (certain proteins or cellular markers found in a blood test) that will inform doctors which patients diagnosed with ANCA-associated vasculitis (AAV) are most likely to be able to stop their medications suppressing their immune systems and remain in remission.

Conditions

  • ANCA-Associated Vasculitis

Interventions

PROCEDURE

Venipuncture for blood sample collection

Analysis samples from the blood sample collection at specific time points.

Sponsors & Collaborators

  • Immune Tolerance Network (ITN)

    collaborator NETWORK

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Alan Salama, MD · University College London, Centre for Nephrology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01934504 on ClinicalTrials.gov